Core Insights - The company Tongshi Technology has been ranked 439th in the "Asia Brand 500" list for 2025, marking a rise of 17 positions from the previous year, and is the only brand in the marine pharmaceuticals and bioproducts sector to be included [1] - Tongshi Technology has maintained its position as the global leader in krill oil sales for two consecutive years, with its VIK brand also being the top-selling domestic brand in China for the same period [3] - The company has made significant investments in research and development, holding 49 intellectual property rights and participating in the formulation of 3 national standards and 9 group standards [4] Product Development and Market Expansion - Tongshi Technology has launched the world's first PQQ small molecule krill peptide, which has generated significant consumer interest [4] - The flagship product, Tongshi VIK blue hat krill oil, is the only domestic product certified for both "maintaining healthy blood lipid levels" and "enhancing immunity," and is now available in 57 Sam's Club locations nationwide [4] - The company's products have been exported to 22 countries and regions, including the UK, France, Germany, and New Zealand, enhancing its global influence [6] Consumer Trust and Quality Assurance - The company has achieved a 40% repurchase rate for its krill oil products, reflecting strong consumer loyalty and trust [6] - Tongshi Technology has established a state-of-the-art transparent production facility in Qingdao, featuring a fully automated production line and stringent quality control measures [6] - The company has successfully produced krill oil with a phospholipid content of 56% and a leak rate controlled to below 0.01%, ensuring consistent quality [6] Strategic Collaborations and Future Plans - The company has initiated strategic collaborations with global leaders in the krill industry and has received patent acceptance for new phospholipid-modified drugs aimed at anti-inflammatory and anti-tumor applications [7] - Tongshi Technology aims to strengthen innovation-driven development and deepen industry-academia-research cooperation to lead breakthroughs in marine pharmaceuticals and bioproducts [9]

Core Insights - The report from the World Brand Lab ranks Fengshi Technology at 439th in the "Asia Brand 500" list for 2025, marking a rise of 17 positions from the previous year, and it is the only brand in the marine pharmaceuticals and bioproducts sector to be included [1] - Fengshi Technology has maintained its position as the global leader in krill oil sales for two consecutive years, with its VIK brand being the top-selling domestic krill oil brand in China [1][2] - The company has made significant investments in R&D, holding 49 intellectual property rights and participating in the formulation of 3 national standards and 9 group standards [1] Product Innovations - In May, Fengshi Technology launched the world's first PQQ small molecule krill peptide, which generated significant consumer interest [2] - The VIK blue hat krill oil product, which is the only domestic krill oil with dual functions of maintaining blood lipid levels and enhancing immunity, was launched in 57 Sam's Club stores nationwide [2] - The company's products are now available in 22 countries and regions, including the UK, France, Germany, and New Zealand [2] Quality and Certifications - Fengshi Technology has achieved a marine phospholipid content of 56% in its krill oil, with a leak rate controlled to below 0.01%, ensuring 100% stable quality [2] - The company has received a 100% compliance certification from the international authority ORIVO for five consecutive years, becoming the first company to achieve ORIVO's "5-year zero defect" quality gold standard certification [2] Strategic Collaborations - The company has initiated a strategic partnership with Norway's Aker to develop a lipid-lowering drug, CaPre, and has collaborated with China Pharmaceutical University on research related to marine peptides for anti-tumor and anti-aging applications [3] - Fengshi Technology aims to enhance innovation-driven development and deepen industry-academia-research cooperation to lead breakthroughs in global marine pharmaceuticals and bioproducts [3]